SCHEMBL16212997

SCHEMBL16212997

Cn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCC(CCN)CC3)nc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.55
▸ CYP2C9 P11712 1/20 0.55
▸ ATP6V1B2 P21281 1/20 0.55
▸ TBXA2R P21731 1/20 0.55
▸ EDNRA P25101 1/20 0.55
▸ TARBP2 Q15633 1/20 0.55
▸ KMT2A Q03164 1/20 0.51
▸ DPP4 P27487 6/20 0.49
▸ CHRM2 P08172 1/20 0.49
▸ DRD1 P21728 1/20 0.49
▸ EPHA2 P29317 1/20 0.47
▸ FLT4 P35916 1/20 0.47
▸ GSK3B P49841 1/20 0.47
▸ RARB P10826 1/20 0.47
▸ TBXAS1 P24557 1/20 0.47
▸ SLC6A3 Q01959 1/20 0.47
▸ KDM4E B2RXH2 3/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ ABCC4 O15439 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16212854 0.87 DPP4 (0.60) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL16213319 0.84 LMNA (0.47) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL9437381 0.83 LMNA (0.66) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL9457439 0.82 DPP4 (0.62) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL9437372 0.82 DPP4 (0.62) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL9437352 0.82 LMNA (0.72) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL28787728 0.81 LMNA (0.76) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL12665422 0.80 LMNA (0.56) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL10391042 0.79 KMT2A (0.53) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL28850749 0.79 ENPP1 (0.40) LMNACYP2C9ATP6V1B2TBXA2REDNRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2991992-B1 QUINOLONE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2018-07-25 — — EP disclosed
US-9540399-B2 Quinolone derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2017-01-10 — — US disclosed
EP-2991992-A1 QUINOLONE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2016-03-09 — — EP disclosed
US-20160060276-A1 QUINOLONE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2016-03-03 — — US disclosed
WO-2014178008-A1 QUINOLONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2014-11-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160060276-A1 QUINOLONE DERIVATIVES NQO2, QARS1, RECQL LMNA 1891/4885CYP2C9 517/4885ATP6V1B2 1016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback